> Back to seminars list

Seminar

Friday, 21st, June 2024
From 11h To 12h30
Centre de recherche - Paris - Amphithéâtre Hélène Martel-Massignac (BDD)

Aberrant epi-transcriptomic alterations contribute to disease progression in breast cancer brain metastasis

1.7 million women globally will face a diagnosis of breast cancer, almost 40% of whom will develop metastatic disease. Breast cancer brain metastasis are a frequent and aggressive form of metastatic spread, with treatment options limited for each of the clinically relevant molecular subtypes. Advanced breast cancer cells display exceptional plasticity, capable of adapting to sequential bouts of therapeutic pressure, as well as the vastly changing environmental landscape. To understand potential drivers and novel targets in brain metastasis we have undertaken multi methyl-omic studies, and identified HRD as a gained vulnerability beyond the classic germline mutations in BRCA1/2 and PALB2. Preliminary pre-clinical studies suggest targeting HRD with PARPi may be an effective strategy for this extended patient population.

Speaker(s)

Prof. Leonie Young
Full Professor, OECI accredited Beaumont RCSI Cancer Centre

Department of Surgery, RCSI

Hosted by

Dr. Celine VALLOT
Research Director - DR2
Dynamique de l'information génétique : bases fondamentales et cancer (DIG-Cancer) (UMR3244)

Institut Curie

Dr. Iro Triantafyllakou
Scientific Project Manager
Dynamique de l'information génétique : bases fondamentales et cancer (DIG-Cancer) (UMR3244)

Institut Curie

Invited by

Dr. Celine VALLOT
Research Director - DR2
Dynamique de l'information génétique : bases fondamentales et cancer (DIG-Cancer) (UMR3244)

Institut Curie

Contact

Dr. Celine VALLOT

Research Director - DR2

Institut Curie

Send an e-mail

Dr. Iro Triantafyllakou

Scientific Project Manager

Institut Curie

Send an e-mail

Learn more

Leonie Young’s research focuses on breast cancer cell adaptation on metastatic progression, with a particular focus on brain metastasis.  The studies are translational, profiling genomic, epigenetic, transcriptomic, epi-transcriptomic and proteomic alterations which occur with disease progression.  Her work is inspired by patient advocates and the goal is ultimately to identify new actionable targets and companion diagnostics to manage advanced disease.   

Leonie is a full professor in the Department of Surgery, RCSI, Scientific Director of the OECI accredited Beaumont RCSI Cancer Centre and Lead of Cancer Research at RCSI.